apoquel® — veterinary medication

Overview

Source: Animal Drugs @ FDA

Proprietary name

apoquel®

Active ingredient

Oclacitinib

Application type

NADA

Sponsor

Zoetis Inc.

Applications on record

1

First published

August 17, 2023

Adverse event reports

Source: openFDA VeDDRA

756

Reports mentioning this ingredient

February 12, 2014 – March 25, 2026

358

Classified serious

per reporter assessment

155

Lack of expected efficacy

resistance signal

6

Human operator exposure

needle-stick or splash

Not a risk measure. Veterinary adverse event reports are influenced by how many animals are treated, reporting practice and product age. Reports do not establish that the product caused the event, and a single report can cover an entire herd or flock. Attribution here is by active ingredient because the source dataset redacts brand names.

Attributed by active ingredient “OCLACITINIB”. Green Book ingredient names and VeDDRA ingredient names do not always agree exactly, so attribution is approximate and labelled as such.

Reported reactions

Source: openFDA VeDDRA

Clinical signs coded in the VICH VeDDRA four-level hierarchy, most frequent first.

Reaction terms reported for this ingredient, by report count.
Reaction (VeDDRA term)	Reports	Relative frequency
Tablets, Abnormal	18
Mixed Product Strength	12
Mixed Product	8
Neoplasia NOS	8
Color, Abnormal	7
Diarrhoea	7
Anorexia	6
Lethargy (see also Central nervous system depression in 'Neurological')	6
Abnormal cytology	6
Physical label missing	5
Behavioural disorder NOS	5
Elevated alanine aminotransferase (ALT)	5
Urinary tract infection	5
Vomiting	5
Decreased appetite	4
Contamination, Foreign Object	4
Pruritus	4
Inappropriate urination	4
Elevated serum alkaline phosphatase (SAP)	4
Weight loss	4

Species affected

Source: openFDA VeDDRA

Dog 701 Cat 2 Horse 1

Regulatory context

New Animal Drug Application (NADA). A pioneer approval evaluated for target animal safety, therapeutic effectiveness, manufacturing controls and — for food-producing species — human food safety including residue depletion.

Extra-label use in food-producing animals is governed by the Animal Medicinal Drug Use Clarification Act of 1994 (AMDUCA) and 21 CFR Part 530. It requires a valid veterinarian-client-patient relationship and is prohibited outright for certain drug classes. Withdrawal times are determined by FARAD, not by this index.

Sources for this page

Animal Drugs @ FDA	FDA CVM	Applications, sponsor, status, withdrawal
Animal & Veterinary Events	FDA CVM	VeDDRA adverse event aggregates by active ingredient